ChartRow logo
Data provided bySource: Twelve Data
JAZZ
$240.71+0.39%
as of close, Nov 17, 2026
☾ AH $240.71 +0.39%
Share this page

JAZZ SEC filings (2026)

CIK 1232524 · Pharmaceutical Preparations (SIC 2834) · incorporated in L2 · fiscal year ends in December

2,181 filings on EDGAR since 2003 · 37 annual, 60 quarterly, 278 current · financial statements · earnings

Latest 10-K
Feb 24, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Nov 2, 2026
quarter to Sep 30, 2026
Latest 8-K
Nov 2, 2026
Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
Last earnings release
Nov 2, 2026
−$4.83 vs −$5.18 · ▲ 7.1%
Filings on file
2,181
since 2003, 1,383 insider forms

What happened, last 12 months#

Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.

November 2026

October 2026

September 2026

August 2026

July 2026

June 2026

May 2026

April 2026

March 2026

February 2026

January 2026

Insider transactions#

What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.

Over the last 13 months insiders sold $65.9M in 28 sales and bought nothing on the open market; 79 other transactions (awards, exercises, tax withholding, gifts and plan purchases).

DateInsider
Nov 6, 2026Form 4COZADD BRUCE CDirectorSold · $16.2M · 68,808 sh
Nov 4, 2026Form 4Carr PatriciaSVP, Chief Accounting OfficerSold · $327K · 1,413 sh
Nov 3, 2026Form 4GALA RENEE DPresident & CEO · DirectorSold · $225K · 1,000 sh · 10b5-1
Nov 2, 2026Form 4COZADD BRUCE CDirectorSold · $1.3M · 6,000 sh · 10b5-1
Oct 6, 2026Form 4GALA RENEE DPresident & CEO · DirectorSold · $473K · 2,000 sh · 10b5-1
Oct 1, 2026Form 4COZADD BRUCE CDirectorSold · $1.4M · 6,000 sh · 10b5-1
Sep 10, 2026Form 4Patil Neena MEVP & Chief Legal OfficerSold · $289K · 1,200 sh · 10b5-1
Sep 8, 2026Form 4GALA RENEE DPresident & CEOSold · $486K · 2,000 sh · 10b5-1
Sep 1, 2026Form 4COZADD BRUCE CDirectorSold · $1.5M · 6,000 sh · 10b5-1
Aug 27, 2026Form 4Iannone RobertEVP, Global Head of R&D & CMOSold · $19.2M · 76,921 sh · 10b5-1
Aug 3, 2026Form 4COZADD BRUCE CDirectorSold · $1.5M · 6,000 sh · 10b5-1
Jul 1, 2026Form 4COZADD BRUCE CDirectorSold · $1.4M · 6,000 sh · 10b5-1
Jun 15, 2026Form 4Smith Mark DouglasDirectorSold · $267K · 1,157 sh · 10b5-1
Jun 10, 2026Form 4Patil Neena MEVP & Chief Legal OfficerSold · $278K · 1,200 sh · 10b5-1
Jun 1, 2026Form 4COZADD BRUCE CDirectorSold · $1.4M · 6,000 sh · 10b5-1
May 28, 2026Form 4Pearce SamanthaEVP, Chief Commercial OfficerSold · $1.6M · 6,907 sh
May 28, 2026Form 4Patil Neena MEVP & Chief Legal OfficerSold · $282K · 1,192 sh · 10b5-1
May 22, 2026Form 4Winningham Rick EDirectorSold · $662K · 2,741 sh
May 22, 2026Form 4McSharry Heather AnnDirectorSold · $482K · 2,000 sh
May 1, 2026Form 4COZADD BRUCE CDirectorSold · $1.2M · 6,000 sh · 10b5-1
Apr 1, 2026Form 4COZADD BRUCE CDirectorSold · $1.1M · 6,000 sh · 10b5-1
Mar 9, 2026Form 4Carr PatriciaSVP, Chief Accounting OfficerSold · $235K · 1,287 sh
Mar 3, 2026Form 4COZADD BRUCE CDirectorSold · $1.1M · 6,000 sh · 10b5-1
Feb 27, 2026Form 4RIEDEL NORBERT GDirectorSold · $656K · 3,415 sh
Feb 27, 2026Form 4Carr PatriciaSVP, Chief Accounting OfficerSold · $213K · 1,117 sh
Feb 26, 2026Form 4Patil Neena MEVP & Chief Legal OfficerSold · $10.7M · 55,600 sh
Feb 26, 2026Form 4Henderson Mary ElizabethSVP, Technical OperationsSold · $1.0M · 5,343 sh
Feb 26, 2026Form 4Carr PatriciaSVP, Chief Accounting OfficerSold · $243K · 1,253 sh
Awards, exercises, withholding and plan purchases · 79 transactions
DateInsider
Nov 6, 2026Form 4COZADD BRUCE CDirectorExercise or conversion · $11.8M · 86,500 sh
Nov 6, 2026Form 4COZADD BRUCE CDirectorExercise or conversion · Non-Qualified Stock Option… · $0 · 85,766 sh
Nov 6, 2026Form 4COZADD BRUCE CDirectorExercise or conversion · Incentive Stock Option (ri… · $0 · 734 sh
Nov 4, 2026Form 4Carr PatriciaSVP, Chief Accounting OfficerExercise or conversion · $175K · 1,250 sh
Nov 4, 2026Form 4Carr PatriciaSVP, Chief Accounting OfficerExercise or conversion · Non-Qualified Stock Option… · $0 · 1,250 sh
Sep 8, 2026Form 4GALA RENEE DPresident & CEOTax withholding · $485K · 1,967 sh · 10b5-1
Sep 8, 2026Form 4Henderson Mary ElizabethSVP, Technical OperationsTax withholding · $347K · 1,427 sh
Aug 31, 2026Form 4Henderson Mary ElizabethSVP, Technical OperationsTax withholding · $505K · 2,092 sh
Aug 31, 2026Form 4McSharry Heather AnnDirectorTax withholding · $448K · 1,855 sh
Aug 31, 2026Form 4Kennedy PatrickDirectorTax withholding · $448K · 1,855 sh
Aug 31, 2026Form 4RIEDEL NORBERT GDirectorTax withholding · $412K · 1,706 sh
Aug 31, 2026Form 4ENRIGHT PATRICK GDirectorTax withholding · $412K · 1,706 sh
Aug 31, 2026Form 4Winningham Rick EDirectorTax withholding · $412K · 1,706 sh
Aug 31, 2026Form 4Smith Mark DouglasDirectorTax withholding · $412K · 1,706 sh
Aug 31, 2026Form 4Hamill LauraDirectorTax withholding · $412K · 1,706 sh
Aug 31, 2026Form 4Cook Jennifer E.DirectorTax withholding · $412K · 1,706 sh
Aug 31, 2026Form 4COZADD BRUCE CDirectorTax withholding · $294K · 1,219 sh · 10b5-1
Aug 31, 2026Form 4LOVE TED WDirectorTax withholding · $179K · 743 sh
Aug 27, 2026Form 4Iannone RobertEVP, Global Head of R&D & CMOExercise or conversion · $7.2M · 57,500 sh · 10b5-1
Aug 27, 2026Form 4Iannone RobertEVP, Global Head of R&D & CMOExercise or conversion · Non-Qualified Stock Option… · $0 · 53,700 sh · 10b5-1
Aug 27, 2026Form 4Iannone RobertEVP, Global Head of R&D & CMOExercise or conversion · Incentive Stock Option (ri… · $0 · 3,800 sh · 10b5-1
Aug 5, 2026Form 4Pearce SamanthaEVP, Chief Commercial OfficerTax withholding · $204K · 780 sh
Aug 5, 2026Form 4RIEDEL NORBERT GDirectorAward · $0 · 1,605 sh
Aug 5, 2026Form 4LOVE TED WDirectorAward · $0 · 1,605 sh
Aug 5, 2026Form 4COZADD BRUCE CDirectorAward · $0 · 1,605 sh
Aug 5, 2026Form 4ENRIGHT PATRICK GDirectorAward · $0 · 1,605 sh
Aug 5, 2026Form 4Winningham Rick EDirectorAward · $0 · 1,605 sh
Aug 5, 2026Form 4Mulligan SeamusDirectorAward · $0 · 1,605 sh
Aug 5, 2026Form 4McSharry Heather AnnDirectorAward · $0 · 1,605 sh
Aug 5, 2026Form 4Hamill LauraDirectorAward · $0 · 1,605 sh
Aug 5, 2026Form 4Cook Jennifer E.DirectorAward · $0 · 1,605 sh
Aug 5, 2026Form 4Smith Mark DouglasDirectorAward · $0 · 1,605 sh
Aug 5, 2026Form 4Kennedy PatrickDirectorAward · $0 · 1,605 sh
Jun 30, 2026Form 4GALA RENEE DPresident & CEOTax withholding · $1.1M · 4,835 sh
Jun 30, 2026Form 4Iannone RobertEVP, Global Head of R&D & CMOTax withholding · $895K · 3,764 sh
Jun 30, 2026Form 4Johnson Philip LEVP & Chief Financial OfficerTax withholding · $795K · 3,343 sh
Jun 30, 2026Form 4Patil Neena MEVP & Chief Legal OfficerTax withholding · $637K · 2,678 sh
Jun 30, 2026Form 4Pearce SamanthaEVP, Chief Commercial OfficerTax withholding · $601K · 2,527 sh
Jun 3, 2026Form 4GALA RENEE DPresident & CEOGift · $0 · 600 sh
May 28, 2026Form 4Pearce SamanthaEVP, Chief Commercial OfficerExercise or conversion · $756K · 6,907 sh
May 28, 2026Form 4Mulligan SeamusDirectorExercise or conversion · $472K · 3,415 sh
May 28, 2026Form 4Pearce SamanthaEVP, Chief Commercial OfficerExercise or conversion · Non-Qualified Stock Option… · $0 · 6,907 sh
May 28, 2026Form 4Mulligan SeamusDirectorExercise or conversion · Non-Qualified Stock Option… · $0 · 3,415 sh
May 22, 2026Form 4Winningham Rick EDirectorExercise or conversion · $472K · 3,415 sh
May 22, 2026Form 4Winningham Rick EDirectorExercise or conversion · Non-Qualified Stock Option… · $0 · 3,415 sh
Mar 5, 2026Form 4COZADD BRUCE CDirectorTax withholding · $2.9M · 15,114 sh
Mar 5, 2026Form 4GALA RENEE DPresident & CEOTax withholding · $1.3M · 7,065 sh
Mar 5, 2026Form 4Iannone RobertEVP, Global Head of R&D & CMOTax withholding · $1.2M · 6,209 sh
Mar 5, 2026Form 4Patil Neena MEVP & Chief Legal OfficerTax withholding · $943K · 5,000 sh
Mar 5, 2026Form 4Johnson Philip LEVP & Chief Financial OfficerTax withholding · $493K · 2,615 sh
Mar 5, 2026Form 4Pearce SamanthaEVP, Chief Commercial OfficerTax withholding · $472K · 2,503 sh
Mar 5, 2026Form 4Carr PatriciaSVP, Chief Accounting OfficerTax withholding · $268K · 1,436 sh
Mar 5, 2026Form 4Henderson Mary ElizabethSVP, Technical OperationsTax withholding · $260K · 1,394 sh
Feb 27, 2026Form 4RIEDEL NORBERT GDirectorExercise or conversion · $472K · 3,415 sh
Feb 27, 2026Form 4RIEDEL NORBERT GDirectorExercise or conversion · Non-Qualified Stock Option… · $0 · 3,415 sh
Feb 26, 2026Form 4Patil Neena MEVP & Chief Legal OfficerExercise or conversion · $6.5M · 51,000 sh
Feb 26, 2026Form 4Patil Neena MEVP & Chief Legal OfficerExercise or conversion · Non-Qualified Stock Option… · $0 · 47,209 sh
Feb 26, 2026Form 4GALA RENEE DPresident & CEOAward · $0 · 44,465 sh
Feb 26, 2026Form 4Iannone RobertEVP, Global Head of R&D & CMOAward · $0 · 14,822 sh
Feb 26, 2026Form 4Johnson Philip LEVP & Chief Financial OfficerAward · $0 · 11,857 sh
Feb 26, 2026Form 4Patil Neena MEVP & Chief Legal OfficerAward · $0 · 10,079 sh
Feb 26, 2026Form 4Pearce SamanthaEVP, Chief Commercial OfficerAward · $0 · 9,782 sh
Feb 26, 2026Form 4Henderson Mary ElizabethSVP, Technical OperationsAward · $0 · 4,447 sh
Feb 26, 2026Form 4Patil Neena MEVP & Chief Legal OfficerExercise or conversion · Incentive Stock Option (ri… · $0 · 3,791 sh
Feb 26, 2026Form 4Carr PatriciaSVP, Chief Accounting OfficerAward · $0 · 2,223 sh
Feb 26, 2026Form 4LOVE TED WDirectorAward · $0 · 1,527 sh
Jan 16, 2026Form 4COZADD BRUCE CDirectorTax withholding · $3.0M · 17,453 sh
Jan 16, 2026Form 4GALA RENEE DPresident & CEOTax withholding · $919K · 5,371 sh
Jan 16, 2026Form 4Iannone RobertEVP, Global Head of R&D & CMOTax withholding · $709K · 4,140 sh
Jan 16, 2026Form 4Patil Neena MEVP & Chief Legal OfficerOther · $561K · 3,275 sh
Jan 16, 2026Form 4Pearce SamanthaEVP, Chief Commercial OfficerTax withholding · $274K · 1,599 sh
Jan 16, 2026Form 4COZADD BRUCE CDirectorAward · $0 · 35,917 sh
Jan 16, 2026Form 4GALA RENEE DPresident & CEOAward · $0 · 12,741 sh
Jan 16, 2026Form 4Iannone RobertEVP, Global Head of R&D & CMOAward · $0 · 11,699 sh
Jan 16, 2026Form 4Henderson Mary ElizabethSVP, Technical OperationsAward · $0 · 10,116 sh
Jan 16, 2026Form 4Patil Neena MEVP & Chief Legal OfficerAward · $0 · 8,852 sh
Jan 16, 2026Form 4Pearce SamanthaEVP, Chief Commercial OfficerAward · $0 · 3,637 sh
Jan 16, 2026Form 4Carr PatriciaSVP, Chief Accounting OfficerAward · $0 · 2,370 sh
Aug 18, 2025Form 4ENRIGHT PATRICK GDirectorOther · $0 · 5,000 sh

Reports and proxy statements#

Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.

2026 · 25 filings
FiledWhat it is
Nov 2, 202610-QQuarterly report, Q3 2026 — revenue $1.24B (+10% y/y), net income −$483.4M, EPS −$7.48
Nov 2, 20268-KEarnings release — EPS −$4.83 vs −$5.18 est. (+6.8%); revenue $1.24B (+10% y/y) 7.1%
Oct 26, 20268-KResults of operations
Oct 9, 20268-KDirectors or officers; compensation
Sep 23, 20268-KMaterial definitive agreement; New financial obligation
Sep 15, 20268-KJazz Pharmaceuticals Completes Acquisition of Actio BiosciencesRegulation FD disclosure
Aug 31, 20268-KJazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share RepurchasesMaterial definitive agreement; New financial obligation; Unregistered sale of equity; Other events
Aug 25, 20268-KU.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal AdenocarcinomaOther events
Aug 10, 20268-KMaterial definitive agreement
Aug 10, 20268-KJazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy PortfolioRegulation FD disclosure
Aug 3, 202610-QQuarterly report, Q2 2026 — revenue $1.21B (+16% y/y), net income $192.8M, EPS $2.78
Aug 3, 20268-KEarnings release — EPS $4.89 vs $5.06 est. (−3.4%); revenue $1.21B (+16% y/y) 4.0%
Jul 24, 20268-KShareholder vote results
Jul 14, 2026DEFA14AAdditional proxy materials
Jun 8, 2026ARSAnnual report to shareholders
Jun 8, 2026DEFA14AAdditional proxy materials
Jun 8, 2026DEF 14AProxy statement
May 29, 2026PRE 14APreliminary proxy statement
May 29, 20268-KDirectors or officers; compensation
May 5, 202610-QQuarterly report, Q1 2026 — revenue $1.07B (+19% y/y), net income $293.1M, EPS $4.43
May 5, 20268-KEarnings release — EPS $5.46 vs $3.82 est. (+42.9%); revenue $1.07B (+19% y/y) 7.7%
Apr 24, 202610-K/AAnnual report, amended
Feb 24, 202610-KAnnual report, FY2025 — revenue $4.27B (+5% y/y), net income −$356.1M, EPS −$5.84
Feb 24, 20268-KEarnings release — EPS $5.76 vs $5.65 est. (+1.9%); revenue $1.20B (+10% y/y) 13.2%
Jan 12, 20268-KResults of operations
2025 · 25 filings
FiledWhat it is
Nov 17, 20258-KOther events
Nov 5, 202510-QQuarterly report, Q3 2025 — revenue $1.13B (+7% y/y), net income $251.4M, EPS $4.08
Nov 5, 20258-KEarnings release — EPS $6.99 vs $4.80 est. (+45.6%); revenue $1.13B (+7% y/y) 2.3%
Oct 28, 20258-KDirectors or officers; compensation
Oct 22, 20258-KOther events
Aug 6, 202510-QQuarterly report, Q2 2025 — revenue $1.05B (+2% y/y), net income −$718.5M, EPS −$11.74
Aug 5, 20258-KEarnings release — EPS −$9.07 vs −$6.47 est. (−40.2%); revenue $1.05B (+2% y/y) 6.4%
Jul 25, 20258-KShareholder vote results
Jul 14, 2025DEFA14AAdditional proxy materials
Jul 10, 2025DEFA14AAdditional proxy materials
Jul 10, 20258-KDirectors or officers; compensation; Regulation FD disclosure
Jun 6, 2025ARSAnnual report to shareholders
Jun 6, 2025DEFA14AAdditional proxy materials
Jun 6, 2025DEF 14AProxy statement
May 23, 2025PRE 14APreliminary proxy statement
May 7, 202510-QQuarterly report, Q1 2025 — revenue $897.8M (−0% y/y), net income −$92.5M, EPS −$1.52
May 6, 20258-KEarnings release — EPS $0.60 vs $3.96 est. (−84.8%); revenue $897.8M (−0% y/y) 8.8%
Apr 25, 202510-K/AAnnual report, amended
Apr 21, 20258-KRegulation FD disclosure; Other events
Apr 8, 20258-KMaterial definitive agreement
Mar 5, 20258-K/AMaterial definitive agreement; Regulation FD disclosure
Mar 5, 20258-KMaterial definitive agreement; Regulation FD disclosure
Feb 26, 202510-KAnnual report, FY2024 — revenue $4.07B (+6% y/y), net income $560.1M, EPS $8.65
Feb 25, 20258-KEarnings release — EPS $5.70 vs $4.98 est. (+14.5%); revenue $1.09B (+8% y/y) 3.2%
Jan 13, 20258-KResults of operations
2024 · 27 filings
FiledWhat it is
Dec 16, 20248-KDirectors or officers; compensation
Nov 26, 20248-KMaterial definitive agreement; New financial obligation
Nov 21, 20248-KOther events
Nov 7, 202410-QQuarterly report, Q3 2024 — revenue $1.05B (+9% y/y), net income $215.1M, EPS $3.42
Nov 6, 20248-KEarnings release — EPS $5.86 vs $4.54 est. (+29.1%); revenue $1.05B (+9% y/y) 6.8%
Oct 16, 20248-KTermination of a material agreement
Sep 6, 20248-KMaterial definitive agreement; New financial obligation; Unregistered sale of equity; Other events
Aug 28, 20248-KOther events
Aug 1, 202410-QQuarterly report, Q2 2024 — revenue $1.02B (+7% y/y), net income $168.6M, EPS $2.49
Jul 31, 20248-KEarnings release — EPS $4.67 vs $3.80 est. (+22.9%); revenue $1.02B (+7% y/y) 3.7%
Jul 26, 20248-KShareholder vote results
Jul 22, 2024DEFA14AAdditional proxy materials
Jul 22, 20248-KMaterial definitive agreement; New financial obligation
Jun 14, 2024ARSAnnual report to shareholders
Jun 14, 2024DEFA14AAdditional proxy materials
Jun 14, 2024DEF 14AProxy statement
Jun 3, 2024PRE 14APreliminary proxy statement
May 31, 20248-KDirectors or officers; compensation
May 2, 202410-QQuarterly report, Q1 2024 — revenue $902.0M (+1% y/y), net income −$14.6M, EPS −$0.23
May 1, 20248-KEarnings release — EPS $1.98 vs $3.53 est. (−43.9%); revenue $902.0M (+1% y/y) 0.9%
Apr 26, 202410-K/AAnnual report, amended
Feb 28, 202410-KAnnual report, FY2023 — revenue $3.83B (+5% y/y), net income $414.8M, EPS $6.10
Feb 28, 20248-KEarnings release — EPS $4.40 vs $4.44 est. (−0.9%); revenue $1.01B (+4% y/y) 8.3%
Feb 27, 20248-KDirectors or officers; compensation
Feb 21, 20248-KDirectors or officers; compensation; Regulation FD disclosure
Jan 25, 20248-KMaterial definitive agreement; New financial obligation
Jan 8, 20248-KResults of operations
2023 · 19 filings — 9 × 8-K, 3 × 10-Q, 2 × DEFA14A and 5 other forms
FiledWhat it is
Nov 8, 202310-QQuarterly report, Q3 2023 — revenue $972.1M (+3% y/y), net income $146.8M, EPS $2.14
Aug 9, 202310-QQuarterly report, Q2 2023 — revenue $957.3M (+3% y/y), net income $104.4M, EPS $1.52
Jul 26, 2023DEFA14AAdditional proxy materials
Jun 16, 2023ARSAnnual report to shareholders
Jun 16, 2023DEFA14AAdditional proxy materials
Jun 16, 2023DEF 14AProxy statement
Jun 6, 2023PRE 14APreliminary proxy statement
May 10, 202310-QQuarterly report, Q1 2023 — revenue $892.8M (+10% y/y), net income $69.4M, EPS $1.04
May 1, 202310-K/AAnnual report, amended
Mar 1, 202310-KAnnual report, FY2022 — revenue $3.66B (+18% y/y), net income −$224.1M, EPS −$3.58

9 current reports (8-K) not listed; the year is on EDGAR.

2022 · 24 filings — 12 × 8-K, 5 × DEFA14A, 3 × 10-Q and 4 other forms
FiledWhat it is
Nov 9, 202210-QQuarterly report, Q3 2022 — revenue $940.7M (+12% y/y), net income −$19.6M, EPS −$0.31
Aug 3, 202210-QQuarterly report, Q2 2022 — revenue $932.9M (+24% y/y), net income $34.7M, EPS $0.55
Jul 22, 2022DEFA14AAdditional proxy materials
Jul 15, 2022DEFA14AAdditional proxy materials
Jul 7, 2022DEFA14AAdditional proxy materials
Jun 17, 2022DEFA14AAdditional proxy materials
Jun 13, 2022DEFA14AAdditional proxy materials
Jun 13, 2022DEF 14AProxy statement
May 31, 2022PRE 14APreliminary proxy statement
May 4, 202210-QQuarterly report, Q1 2022 — revenue $813.7M (+34% y/y), net income $1.6M, EPS $0.03
May 2, 202210-K/AAnnual report, amended
Mar 1, 202210-KAnnual report, FY2021 — revenue $3.09B (+31% y/y), net income −$329.7M, EPS −$5.52

12 current reports (8-K) not listed; the year is on EDGAR.

2021 · 47 filings — 17 × 8-K, 15 × DFAN14A, 5 × DEFA14A and 6 other forms
FiledWhat it is
Nov 9, 202110-QQuarterly report, Q3 2021 — revenue $838.1M (+39% y/y), net income −$52.8M, EPS −$0.86
Aug 30, 2021DEF 14AProxy statement
Aug 19, 2021PRE 14APreliminary proxy statement
Aug 3, 202110-QQuarterly report, Q2 2021 — revenue $751.8M (+34% y/y), net income −$363.3M, EPS −$6.11
Jul 26, 2021DEFA14AAdditional proxy materials
Jul 15, 2021DEFA14AAdditional proxy materials
Jul 14, 2021DEFA14AAdditional proxy materials
Jul 14, 2021DEFA14AAdditional proxy materials
Jun 11, 2021DEFA14AAdditional proxy materials
Jun 11, 2021DEF 14AProxy statement
Jun 1, 2021PRE 14APreliminary proxy statement
May 4, 202110-QQuarterly report, Q1 2021 — revenue $607.6M (+14% y/y), net income $121.8M, EPS $2.09
Apr 23, 202110-K/AAnnual report, amended
Apr 20, 2021DFAN14AProxy statements
Mar 23, 2021DFAN14AProxy statements
Feb 26, 2021DFAN14AProxy statements
Feb 24, 2021DFAN14AProxy statements
Feb 24, 2021DFAN14AProxy statements
Feb 24, 2021DFAN14AProxy statements
Feb 23, 202110-KAnnual report, FY2020 — revenue $2.36B (+9% y/y), net income $238.6M, EPS $4.22
Feb 23, 2021DFAN14AProxy statements
Feb 9, 2021DFAN14AProxy statements
Feb 8, 2021DFAN14AProxy statements
Feb 5, 2021DFAN14AProxy statements
Feb 4, 2021DFAN14AProxy statements
Feb 4, 2021DFAN14AProxy statements
Feb 4, 2021DFAN14AProxy statements
Feb 4, 2021DFAN14AProxy statements
Feb 3, 2021DFAN14AProxy statements

18 current reports (8-K) not listed; the year is on EDGAR.

2020 · 20 filings — 10 × 8-K, 3 × 10-Q, 3 × DEFA14A and 4 other forms
FiledWhat it is
Nov 2, 202010-QQuarterly report, Q3 2020 — revenue $600.9M (+12% y/y), net income $148.2M, EPS $2.64
Aug 4, 202010-QQuarterly report, Q2 2020 — revenue $562.4M (+5% y/y), net income $114.8M, EPS $2.06
Jul 22, 2020DEFA14AAdditional proxy materials
Jul 21, 2020DEFA14AAdditional proxy materials
Jun 12, 2020DEFA14AAdditional proxy materials
Jun 12, 2020DEF 14AProxy statement
Jun 2, 2020PRE 14APreliminary proxy statement
May 5, 202010-QQuarterly report, Q1 2020 — revenue $534.7M (+5% y/y), net income −$157.8M, EPS −$2.82
Apr 24, 202010-K/AAnnual report, amended
Feb 25, 202010-KAnnual report, FY2019 — revenue $2.16B (+14% y/y), net income $523.4M, EPS $9.09

10 current reports (8-K) not listed; the year is on EDGAR.

2019 · 19 filings — 11 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
FiledWhat it is
Nov 5, 201910-QQuarterly report, Q3 2019 — revenue $537.7M (+15% y/y), net income $102.3M, EPS $1.78
Aug 6, 201910-QQuarterly report, Q2 2019 — revenue $534.1M (+7% y/y), net income $261.9M, EPS $4.56
Jun 14, 2019DEFA14AAdditional proxy materials
Jun 14, 2019DEFA14AAdditional proxy materials
Jun 14, 2019DEF 14AProxy statement
May 7, 201910-QQuarterly report, Q1 2019 — revenue $508.2M (+14% y/y), net income $85.2M, EPS $1.47
Apr 26, 201910-K/AAnnual report, amended
Feb 26, 201910-KAnnual report, FY2018 — revenue $1.89B (+17% y/y), net income $447.1M, EPS $7.30

11 current reports (8-K) not listed; the year is on EDGAR.

2018 · 18 filings — 10 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
FiledWhat it is
Nov 6, 201810-QQuarterly report, Q3 2018 — revenue $469.4M (+14% y/y), net income $149.3M, EPS $2.41
Aug 7, 201810-QQuarterly report, Q2 2018 — revenue $500.5M (+27% y/y), net income $92.3M, EPS $1.50
Jun 15, 2018DEFA14AAdditional proxy materials
Jun 15, 2018DEFA14AAdditional proxy materials
Jun 15, 2018DEF 14AProxy statement
May 8, 201810-QQuarterly report, Q1 2018 — revenue $444.6M (+18% y/y), net income $46.0M, EPS $0.75
Apr 24, 201810-K/AAnnual report, amended
Feb 27, 201810-KAnnual report, FY2017 — revenue $1.62B (+9% y/y), net income $487.8M, EPS $7.96

10 current reports (8-K) not listed; the year is on EDGAR.

2017 · 21 filings — 12 × 8-K, 3 × 10-Q, 2 × DEFA14A and 4 other forms
FiledWhat it is
Nov 7, 201710-QQuarterly report, Q3 2017 — revenue $411.9M (+10% y/y), net income $63.5M, EPS $1.03
Aug 8, 201710-QQuarterly report, Q2 2017 — revenue $394.4M (+3% y/y), net income $105.6M, EPS $1.72
Jun 20, 2017DEFA14AAdditional proxy materials
Jun 20, 2017DEFA14AAdditional proxy materials
Jun 20, 2017DEF 14AProxy statement
Jun 5, 2017PRE 14APreliminary proxy statement
May 9, 201710-QQuarterly report, Q1 2017 — revenue $376.1M (+12% y/y), net income $86.5M, EPS $1.41
Apr 25, 201710-K/AAnnual report, amended
Feb 28, 201710-KAnnual report, FY2016 — revenue $1.49B (+12% y/y), net income $396.8M, EPS $6.41

12 current reports (8-K) not listed; the year is on EDGAR.

2016 · 22 filings — 8 × 8-K, 5 × DEFA14A, 3 × 10-Q and 5 other forms

Counted, not listed; the year is on EDGAR.

2015 · 20 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2014 · 25 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 5 other forms

Counted, not listed; the year is on EDGAR.

2013 · 21 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 5 other forms

Counted, not listed; the year is on EDGAR.

2012 · 35 filings — 27 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2011 · 23 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2010 · 23 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2009 · 26 filings — 15 × 8-K, 3 × 10-Q, 2 × 10-K/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2008 · 24 filings — 18 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2007 · 7 filings — 5 × 8-K, 2 × 10-Q

Counted, not listed; the year is on EDGAR.

Insider, ownership and other filings#

Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.

2026 · 125 filings — 77 × 4, 44 × 144, 2 × SCHEDULE 13G and 1 other form
FiledWhat it is
Nov 10, 20264Insider transaction (Form 4)
Nov 6, 20264Insider transaction (Form 4)
Nov 6, 2026144Notice of proposed sale (Form 144)
Nov 5, 20264Insider transaction (Form 4)
Nov 5, 2026SCHEDULE 13G/AOther filings
Nov 4, 20264Insider transaction (Form 4)
Nov 4, 2026144Notice of proposed sale (Form 144)
Nov 3, 2026144Notice of proposed sale (Form 144)
Nov 2, 2026144Notice of proposed sale (Form 144)
Oct 8, 2026144Notice of proposed sale (Form 144)
Oct 7, 20264Insider transaction (Form 4)
Oct 6, 2026144Notice of proposed sale (Form 144)
Oct 5, 20264Insider transaction (Form 4)
Oct 1, 2026144Notice of proposed sale (Form 144)
Sep 14, 20264Insider transaction (Form 4)
Sep 10, 20264Insider transaction (Form 4)
Sep 10, 20264Insider transaction (Form 4)
Sep 10, 2026144Notice of proposed sale (Form 144)
Sep 8, 2026144Notice of proposed sale (Form 144)
Sep 8, 2026144Notice of proposed sale (Form 144)
Sep 2, 20264Insider transaction (Form 4)
Sep 2, 20264Insider transaction (Form 4)
Sep 2, 20264Insider transaction (Form 4)
Sep 2, 20264Insider transaction (Form 4)
Sep 2, 20264Insider transaction (Form 4)

The newest 25 of 125 shown; the full year is on EDGAR.

2025 · 115 filings — 58 × 4, 38 × 144, 9 × SC TO-T/A and 5 other forms
FiledWhat it is
Dec 11, 20254Insider transaction (Form 4)
Dec 10, 20253Initial insider holdings (Form 3)
Dec 9, 2025144Notice of proposed sale (Form 144)
Dec 9, 20254Insider transaction (Form 4)
Dec 9, 20254Insider transaction (Form 4)
Dec 5, 2025144Notice of proposed sale (Form 144)
Dec 4, 20254Insider transaction (Form 4)
Dec 1, 2025144Notice of proposed sale (Form 144)
Dec 1, 20254Insider transaction (Form 4)
Nov 26, 2025144Notice of proposed sale (Form 144)
Nov 24, 20254Insider transaction (Form 4)
Nov 21, 20254Insider transaction (Form 4)
Nov 20, 20254Insider transaction (Form 4)
Nov 20, 20254Insider transaction (Form 4)
Nov 20, 20254Insider transaction (Form 4)
Nov 20, 2025144Notice of proposed sale (Form 144)
Nov 19, 2025144Notice of proposed sale (Form 144)
Nov 19, 20254Insider transaction (Form 4)
Nov 18, 2025144Notice of proposed sale (Form 144)
Nov 18, 2025144Notice of proposed sale (Form 144)
Nov 18, 2025144Notice of proposed sale (Form 144)
Nov 17, 2025144Notice of proposed sale (Form 144)
Oct 3, 20254Insider transaction (Form 4)
Oct 3, 2025144Notice of proposed sale (Form 144)
Sep 17, 20254Insider transaction (Form 4)

The newest 25 of 115 shown; the full year is on EDGAR.

2024 · 67 filings — 42 × 4, 17 × 144, 4 × SC 13G/A and 2 other forms
FiledWhat it is
Dec 9, 20244Insider transaction (Form 4)
Dec 4, 20244Insider transaction (Form 4)
Dec 4, 20244Insider transaction (Form 4)
Dec 2, 2024144Notice of proposed sale (Form 144)
Dec 2, 2024144Notice of proposed sale (Form 144)
Nov 13, 20244Insider transaction (Form 4)
Nov 12, 2024SC 13G/APassive holder above 5% (Schedule 13G), amended
Nov 8, 2024144Notice of proposed sale (Form 144)
Nov 5, 20244Insider transaction (Form 4)
Nov 1, 2024144Notice of proposed sale (Form 144)
Oct 21, 2024SC 13G/APassive holder above 5% (Schedule 13G), amended
Sep 11, 20244Insider transaction (Form 4)
Sep 5, 2024144Notice of proposed sale (Form 144)
Aug 6, 20244Insider transaction (Form 4)
Aug 6, 20244Insider transaction (Form 4)
Aug 6, 20244Insider transaction (Form 4)
Aug 6, 20244Insider transaction (Form 4)
Aug 6, 20244Insider transaction (Form 4)
Aug 6, 20244Insider transaction (Form 4)
Aug 6, 20244Insider transaction (Form 4)
Aug 6, 20244Insider transaction (Form 4)
Aug 6, 20244Insider transaction (Form 4)
Aug 6, 20244Insider transaction (Form 4)
Aug 6, 20244Insider transaction (Form 4)
Aug 6, 20244Insider transaction (Form 4)

The newest 25 of 67 shown; the full year is on EDGAR.

2023 · 68 filings — 44 × 4, 17 × 144, 4 × SC 13G/A and 3 other forms

Counted, not listed; the year is on EDGAR.

2022 · 74 filings — 67 × 4, 4 × SC 13G/A, 1 × 5 and 2 other forms

Counted, not listed; the year is on EDGAR.

2021 · 70 filings — 63 × 4, 3 × SC 13G/A, 2 × S-8 and 2 other forms

Counted, not listed; the year is on EDGAR.

2020 · 76 filings — 56 × 4, 5 × 3, 4 × CT ORDER and 6 other forms

Counted, not listed; the year is on EDGAR.

2019 · 60 filings — 44 × 4, 5 × 3, 4 × SC 13G/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2018 · 88 filings — 76 × 4, 4 × SC 13G/A, 3 × CT ORDER and 4 other forms

Counted, not listed; the year is on EDGAR.

2017 · 74 filings — 65 × 4, 4 × SC 13G/A, 2 × CT ORDER and 3 other forms

Counted, not listed; the year is on EDGAR.

2016 · 97 filings — 78 × 4, 4 × SC TO-T/A, 3 × SC 13G/A and 8 other forms

Counted, not listed; the year is on EDGAR.

2015 · 97 filings — 84 × 4, 3 × CORRESP, 3 × CT ORDER and 6 other forms

Counted, not listed; the year is on EDGAR.

2014 · 124 filings — 90 × 4, 11 × SC TO-T/A, 5 × 3 and 11 other forms

Counted, not listed; the year is on EDGAR.

2013 · 88 filings — 65 × 4, 5 × CORRESP, 4 × UPLOAD and 10 other forms

Counted, not listed; the year is on EDGAR.

2012 · 133 filings — 75 × 4, 18 × 3, 6 × S-8 POS and 17 other forms

Counted, not listed; the year is on EDGAR.

2011 · 75 filings — 42 × 4, 19 × 425, 5 × 3 and 5 other forms

Counted, not listed; the year is on EDGAR.

2010 · 62 filings — 39 × 4, 4 × EFFECT, 4 × POS AM and 8 other forms

Counted, not listed; the year is on EDGAR.

2009 · 64 filings — 28 × 4, 6 × SC 13G/A, 3 × 3 and 14 other forms

Counted, not listed; the year is on EDGAR.

2008 · 79 filings — 47 × 4, 7 × 4/A, 7 × SC 13G and 9 other forms

Counted, not listed; the year is on EDGAR.

2007 · 65 filings — 31 × 4, 16 × 3, 5 × S-1/A and 10 other forms

Counted, not listed; the year is on EDGAR.

2006 · 2 filings — 2 × REGDEX/A

Counted, not listed; the year is on EDGAR.

2005 · 2 filings — 1 × REGDEX, 1 × SC 13D

Counted, not listed; the year is on EDGAR.

2004 · 3 filings — 2 × REGDEX/A, 1 × REGDEX

Counted, not listed; the year is on EDGAR.

2003 · 2 filings — 1 × REGDEX, 1 × REGDEX/A

Counted, not listed; the year is on EDGAR.

About this data#

Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ) has 2,181 filings on EDGAR going back to 2003: 37 annual reports, 60 quarterly reports and 278 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Nov 2, 2026, furnished a press release headed “Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results”. Over the last 13 months insiders sold $65.9M in 28 sales and bought nothing on the open market; 79 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.

Every row is a filing EDGAR lists for the registrants that have been Jazz Pharmaceuticals plc Common Stock (Ireland), read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.

FAQ#

Where can I read JAZZ's latest 10-K?
JAZZ's latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
When did JAZZ last file an 8-K?
On Nov 2, 2026 it furnished a press release headed “Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Nov 2, 2026.
Are JAZZ insiders buying or selling?
Over the last 13 months insiders sold $65.9M in 28 sales and bought nothing on the open market; 79 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: COZADD BRUCE C (Director) sold 68,808 shares on Nov 6, 2026 for $16.2M. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
How many SEC filings has JAZZ made?
2,181 filings are on EDGAR under the registrant records that have been Jazz Pharmaceuticals plc Common Stock (Ireland), going back to 2003; 1,383 of them are insider ownership forms (Forms 3, 4, 5 and 144).